Although clinicians and patients were hoping that the recent rofecoxib
debacle would be isolated to that drug alone, new clinical trial data now
indicate that other nonsteroidal anti-inflammatory drugs (NSAIDs) may, like
rofecoxib, raise the risk of heart attack and stroke. As patients and physicians
wait for a clear analysis of the available data, they are left wondering about
not only the safety of NSAIDs, but also the fate of clinical studies testing
the drugs’ effectiveness for preventing other conditions.
Hampton T. Officials Halt NSAID Prevention Trials. JAMA. 2005;293(6):664-665. doi:10.1001/jama.293.6.664